
Keywords: اینترفرون; anti-programmed cell death-1 therapy; nivolumab; pembrolizumab; vitiligo; vitiligo-like lesions; Abs; antibodies; CXCL; C-X-C motif ligand; CXCR; C-X-C motif receptor; IFN; interferon; IL; interleukin; PD; programmed cell death; TNF; tumor necrosis fact